Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) were down 9% during trading on Wednesday . The company traded as low as $2.32 and last traded at $2.32. Approximately 188,341 shares were traded during trading, an increase of 66% from the average daily volume of 113,212 shares. The stock had previously closed at $2.55.
iBio Stock Up 7.2 %
The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average price is $2.39 and its 200-day moving average price is $2.19.
iBio Company Profile
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- What is a Low P/E Ratio and What Does it Tell Investors?
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- What is the Hang Seng index?
- Top-Performing Non-Leveraged ETFs This Year
- What is the Dogs of the Dow Strategy? Overview and Examples
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
